Volunteer opportunity: Organizing Phoenix Rising articles
This section contains all the articles that have been published by Phoenix Rising over the years. As you will see if you browse here, some of the articles are outdated--either the research has been superseded or retracted or the article features an event or campaign that is now in...
Discuss the article on the Forums.

HIV and MS: Could a Link Lead to New MS Treatment? Medpagetoday

Discussion in 'Other Health News and Research' started by natasa778, Mar 21, 2014.

  1. natasa778

    natasa778 Senior Member

  2. Ecoclimber

    Ecoclimber Senior Member

    PLoS One. 2013; 8(11): e78474.
    Published online Nov 13, 2013. doi: 10.1371/journal.pone.0078474
    PMCID: PMC3827255
    Activation of MSRV-Type Endogenous Retroviruses during Infectious Mononucleosis and Epstein-Barr Virus Latency: The Missing Link with Multiple Sclerosis?
    Giuseppe Mameli,1 Giordano Madeddu,2 Alessandra Mei,1 Elena Uleri,1 Luciana Poddighe,1 Lucia G. Delogu,3 Ivana Maida,2 Sergio Babudieri,2 Caterina Serra,1 Roberto Manetti,2 Maria S. Mura,2 and Antonina Dolei1,*
    James P. Stewart, Editor

    The etiology of multiple sclerosis (MS) is still unclear. The immuno-pathogenic phenomena leading to neurodegeneration are thought to be triggered by environmental (viral?) factors operating on predisposing genetic backgrounds.
    Among the proposed co-factors are the Epstein Barr virus (EBV), and the potentially neuropathogenic HERV-W/MSRV/Syncytin-1 endogenous retroviruses. The ascertained links between EBV and MS are history of late primary infection, possibly leading to infectious mononucleosis (IM), and high titers of pre-onset IgG against EBV nuclear antigens (anti-EBNA IgG).

    During MS, there is no evidence of MS-specific EBV expression, while a continuous expression of HERV-Ws occurs, paralleling disease behaviour. We found repeatedly extracellular HERV-W/MSRV and MSRV-specific mRNA sequences in MS patients (in blood, spinal fluid, and brain samples), and MRSV presence/load strikingly paralleled MS stages and active/remission phases.

    Aim of the study was to verify whether HERV-W might be activated in vivo, in hospitalized young adults with IM symptoms, that were analyzed with respect to expression of HERV-W/MSRV transcripts and proteins. Healthy controls were either EBV-negative or latently EBV-infected with/without high titers of anti-EBNA-1 IgG.

    The results show that activation of HERV-W/MSRV occurs in blood mononuclear cells of IM patients (2Log10 increase of MSRV-type env mRNA accumulation with respect to EBV-negative controls). When healthy controls are stratified for previous EBV infection (high and low, or no anti-EBNA-1 IgG titers), a direct correlation occurs with MSRV mRNA accumulation. Flow cytometry data show increased percentages of cells exposing surface HERV-Wenv protein, that occur differently in specific cell subsets, and in acute disease and past infection.

    Thus, the data indicate that the two main links between EBV and MS (IM and high anti-EBNA-1-IgG titers) are paralleled by activation of the potentially neuropathogenic HERV-W/MSRV. These novel findings suggest HERV-W/MSRV activation as the missing link between EBV and MS, and may open new avenues of intervention.

    Mult Scler. 2014 Mar;20(3):286-94. doi: 10.1177/1352458513498829. Epub 2013 Jul 25.
    Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
    Strautins K1, Tschochner M, James I, Choo L, Dunn D, Pedrini M, Kermode A, Carroll W, Nolan D.
    Author information

    Risk factors for multiple sclerosis (MS) include human leukocyte antigen (HLA)-DR and Epstein-Barr virus (EBV)-specific antibody responses, including an epitope within EBV nuclear antigen 1 (EBNA-1) that is of recent interest.

    The objective of this paper is to assess case-control associations between MS risk and anti-EBV antibody levels as well as HLA-DR profiles, gender and age in a population-based cohort.

    Serological responses to EBV were measured in 426 MS patients and 186 healthy controls. HLA-DR typing was performed using sequence-based methods.

    MS patients had significantly higher levels of antibodies against epitope-specific and polyspecific EBNA-1 and viral capsid antigen (VCA), compared with controls (all p < 10(-15)). In regression analyses, anti-EBNA-1 and anti-VCA antibody levels, protective HLA-DR*04/07/09 alleles and gender (all p < 0.003) contributed independently to a model that classified cases and controls with an odds ratio > 20 (sensitivity 92%, specificity 64%). Notably, the strong influence of high-risk HLA-DR alleles was abrogated after inclusion of EBV serology results.

    The ability to discriminate MS cases and controls can be substantially enhanced by including anti-EBV serology as well as HLA-DR risk profiles. These findings support the relevance of EBV-specific immunity in MS pathogenesis, and implicate both HLA-dependent and HLA-independent immune responses against EBNA-1 as prominent disease risk factors.

    EBV, ELISA, HLA, Multiple sclerosis, genetics, immunology
    Jon_Tradicionali and shannah like this.
  3. Ecoclimber

    Ecoclimber Senior Member

    Gavin is really one of the good guys and his other Mouse Doctor researchers are superb. They think outside of the box. They are willing to shift the paradigm for MS. They do not have the tunnel vision that some researchers get when focusing on a specific disease category for a specific set of time. He is willing to look at the etilogy and epidemiology of similar diseases to determine if there is a possible associations that could be useful. He calls it The Black Swan which I have posted on here in another thread.http://forums.phoenixrising.me/inde...-cells-using-immunotherapy.28058/#post-427496

See more popular forum discussions.

Share This Page